Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TAP’s Prevacid PAP Is Available To Part D Beneficiaries; Bristol-Myers Squibb To Focus On Coalition Approach

This article was originally published in The Pink Sheet Daily

Executive Summary

TAP extended its Prevacid prescription assistant program to Medicare drug plan enrollees whose household income is between 135% and 200% of the federal poverty level.

You may also be interested in...

Enbrel Growth Plans Include Copay Assistance, DTC

Market share has stabilized but Amgen acknowledges that the TNF inhibitor “isn’t performing up to our expectations.”

Biden's Drug Pricing Administrative Actions Could Focus On Medicare Demos

Center for American Progress suggests pricing reforms for the 'next Administration' in lieu of legislation.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts